CALIXAR team will attend the online Redefining Early-Stage Investments (RESI) event, from March 22 to 24, 2022 to present its licensing business model and to develop a pipeline of native targets of pharmaceutical interest.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, ion channels, transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025.
About the Redefining Early-Stage Investments (RESI)
The Redefining Early-Stage Investments (RESI) conference series connect start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics, and digital health (4 Ds). RESI caters for both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms seeking for series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.
For more information and meet us: Redefining Early Stage Investments (RESI)